In Q1 2026, Olaplex demonstrated robust liquidity with a current ratio above 6, supported by $326 million in cash against manageable net debt. The company advances toward closing its transformative $1.4 billion merger with Henkel, contingent on regulatory approvals across multiple jurisdictions—a process fraught with execution risk. Strategic growth catalysts include the 2025 acquisition of Purvala Bioscience, augmenting Olaplex’s bioinspired technology platform to fuel innovation and strengthen competitive differentiation in the haircare segment. Market challenges and deal uncertainties remain key risk factors that could materially influence operational trajectories.